WUXI XDC Unit Secures Control of TOT BIOPHARM as Cash Offers Turn Unconditional

TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has shared an update.

WUXI XDC Cayman Inc., through its unit BioDlink International Company Limited, has launched voluntary conditional cash offers to acquire all issued shares of TOT BIOPHARM International Co. Ltd. that it does not already own and to cancel all outstanding share options. The offers target control of the Hong Kong-listed oncology-focused biopharmaceutical group, which develops and commercializes cancer therapies in Greater China and beyond.

The offers have now become unconditional in all respects after the offeror secured valid acceptances for approximately 60% of TOT BIOPHARM’s issued share capital and voting rights and about 85% of the company’s outstanding share options by 4:00 p.m. on 17 March 2026. This marks a decisive shift in control that could reshape TOT BIOPHARM’s strategic direction and governance, with implications for remaining minority shareholders as the new controlling shareholder consolidates its position in the regional biopharma sector.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

More about TOT BIOPHARM International Co. Ltd.

TOT BIOPHARM International Co. Ltd. is a Hong Kong-listed biopharmaceutical company focused on the research, development, manufacturing and commercialization of oncology treatments. The company targets cancer therapeutics markets in Greater China and internationally, leveraging biologics and other advanced modalities to address unmet medical needs in oncology.

Average Trading Volume: 4,076,331

Technical Sentiment Signal: Buy

Current Market Cap: HK$3.25B

Find detailed analytics on 1875 stock on TipRanks’ Stock Analysis page.